Sep 28, 2026
AbbVie (ABBV) Stock: FDA Greenlights Innovative Parkinson’s Treatment Juvmo
AbbVie (ABBV) gains FDA approval for Juvmo, a first-in-class Parkinson's treatment launching October 2026. Stock dips 0.29% despite breakthrough.
The post AbbVie (ABBV) Stock: FDA Greenlights Innovative Parkinson’s Treatment Juvmo appeared first on Blockonomi.
Source: Blockonomi →Related News
- 2 hours ago
Hyperliquid Strategies Inc. (PURR) Stock: Shares Climb as Company Boosts Buyback...
- 2 hours ago
Ionis Pharmaceuticals (IONS) Stock: Falls 2.23% Despite Roche’s Breakthrough Pha...
- 3 hours ago
Hyperscale Data, Inc. (GPUS) Stock: Soars 34% as Michigan AI Data Center Nears D...
- 4 hours ago
Edible Garden AG (EDBL) Stock Falls Despite New Farm Partnership Targeting 19% G...
- 7 hours ago
Rocket Lab (RKLB) Stock: Surges as Electron Completes 98th Launch for HawkEye 36...